These data indicate that SRSF2 and RUNX1 mutations promote an aberrant maturation of erythroid cells in low-risk MDS, and importantly, that the disease phenotype observed in the patient could be reproduced in vitro. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.